(Health-NewsWire.Net, December 22, 2016 ) The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Get Complete Report at http://www.reportsweb.com/dementia-pipeline-review-h1-2015
Report Scope
- The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews pipeline therapeutics for Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Dementia therapeutics and enlists all their major and minor projects - The report assesses Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Dementia
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001170060/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Dementia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Ask for Discount at http://www.reportsweb.com/inquiry&RW0001170060/discount
List of Tables
Number of Products under Development for Dementia, H1 2015 13 Number of Products under Development for Dementia-Comparative Analysis, H1 2015 14 Number of Products under Development by Companies, H1 2015 16 Number of Products under Development by Companies, H1 2015 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H1 2015 19 Comparative Analysis by Late Stage Development, H1 2015 20 Comparative Analysis by Clinical Stage Development, H1 2015 21 Comparative Analysis by Early Stage Development, H1 2015 22 Products under Development by Companies, H1 2015 23 Products under Development by Companies, H1 2015 (Contd..1) 24 Products under Development by Companies, H1 2015 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2015 26 Dementia-Pipeline by Actinogen Limited, H1 2015 27 Dementia-Pipeline by Alector LLC, H1 2015 28 Dementia-Pipeline by AlzProtect SAS, H1 2015 29 Dementia-Pipeline by BioArctic Neuroscience AB, H1 2015 30 Dementia-Pipeline by Biogen Idec Inc., H1 2015 31
List of Figures
Number of Products under Development for Dementia, H1 2015 13 Number of Products under Development for Dementia-Comparative Analysis, H1 2015 14 Number of Products under Development by Companies, H1 2015 15 Number of Products under Investigation by Universities/Institutes, H1 2015 18 Comparative Analysis by Clinical Stage Development, H1 2015 21 Comparative Analysis by Early Stage Products, H1 2015 22 Assessment by Monotherapy Products, H1 2015 60 Number of Products by Top 10 Targets, H1 2015 61 Number of Products by Stage and Top 10 Targets, H1 2015 61 Number of Products by Top 10 Mechanism of Actions, H1 2015 64 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 64 Number of Products by Top 10 Routes of Administration, H1 2015 66 Number of Products by Stage and Top 10 Routes of Administration, H1 2015 67
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|